Updates are available Correction dated 2021-10-07
Click to view Correction: https://doi.org/10.1007/s40272-021-00474-y
-
Authors
Esposito, Susanna http://orcid.org/0000-0003-4103-2837
Carrothers, Timothy J.
Riccobene, Todd
Stone, Gregory G.
Kantecki, Michal
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 16 August 2021
First Online: 31 August 2021
Change Date: 7 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40272-021-00474-y
Declarations
:
: Medical writing support for the development of this manuscript was funded by Pfizer. Ceftaroline fosamil is being developed by Pfizer and AbbVie (following its acquisition of Allergan). No payments or honoraria were made to the authors with respect to manuscript preparation.
: Susanna Esposito has received honoraria from Pfizer for speaker presentations in international meetings. Gregory G. Stone and Michal Kantecki are employees of and shareholders in Pfizer. Todd Riccobene is an employee and stockholder of AbbVie (following its acquisition of Allergan). Timothy J. Carrothers is a former employee of AbbVie (following its acquisition of Allergan).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Medical writing support was provided by Melanie More, BSc., CMPP, of Prime Medica Ltd, Knutsford, Cheshire, UK, and was funded by Pfizer.
